Nanomedicine‐Based Immunotherapy for the Treatment of Cancer Metastasis
- 30 September 2019
- journal article
- review article
- Published by Wiley in Advanced Materials
- Vol. 31 (49) , e1904156
Abstract
Metastasis is the leading cause of cancer‐associated death, with poor prognosis even after extensive treatment. The dormancy of metastatic cancer cells during dissemination or after colony formation is one major reason for treatment failure, as most drugs target cells of active proliferation. Immunotherapy has shown great potential in cancer therapy because the activity of effector cells is less affected by the metabolic status of cancer cells. In addition, metastatic cells out of immunosuppressive tumor microenvironment (TME) are more susceptible to immune clearance, although these cells can achieve immune surveillance evasion via strategies such as platelet and macrophage recruitment. Since nanomaterials themselves or their carried drugs have the capability to modulate the immune system, a great amount of focus has been placed on nanomedicine strategies that leverage immune cells participating the metastatic cascade. These nanomedicines successfully inhibit the tumor metastasis and prolong the survival of model animals. Immune cells that are involved in the metastasis cascade are first summarized and then recent and inspiring strategies and nanomaterials in this growing field are highlighted.Keywords
Funding Information
- National Natural Science Foundation of China (81690265, 31870995, 81671808, 81630052)
- Youth Innovation Promotion Association of the Chinese Academy of Sciences (2017335)
This publication has 168 references indexed in Scilit:
- ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophagesCell Research, 2013
- Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapyNature Materials, 2012
- A CXCL1 Paracrine Network Links Cancer Chemoresistance and MetastasisCell, 2012
- In vivo modulation of dendritic cells by engineered materials: Towards new cancer vaccinesNano Today, 2011
- Cancer Nanotheranostics: Improving Imaging and Therapy by Targeted Delivery Across Biological BarriersAdvanced Materials, 2011
- Nuocytes represent a new innate effector leukocyte that mediates type-2 immunityNature, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Microenvironmental regulation of metastasisNature Reviews Cancer, 2008
- Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasisNature Cell Biology, 2006
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002